Storia in 5 fonti

With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma

The FDA has approved a new | The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard-of-care for patients with breast cancer.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

fiercepharma.comStai leggendo1 mese fa

With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big…

The FDA has approved a new | The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard-of-care for patients with breast cancer.

originale

Timeline cronologica

lunedì 13 luglio 2026·fiercepharma.com
Clinical Success Is No Longer One Number
By Andreas Dimakakos Director of Clinical Data, Kate Smietana Director, Knowledge and Thought Leadership, Panos Karelis VP of Commercial, Dimitris Skaltsas Co-founder & CEO | In…
martedì 14 luglio 2026·fiercepharma.com
Cellares' recent automated cell therapy wins have 'opened the biotech floodgates'
After speedrunning a series of major manufacturing milestones in the past year and a half, the “biotech floodgates” have opened for Cellares, the automated cell therapy…

With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma

Confronto fonti

With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big…

Timeline cronologica

Clinical Success Is No Longer One Number

Cellares' recent automated cell therapy wins have 'opened the biotech floodgates'

Correction to Celcuity Gets FDA Approval Headline

Celcuity wins approval for breast cancer drug Revtorpyk

Celcuity gains FDA approval for closely watched breast cancer drug

Celcuity's breast cancer drug approved, its first

Celcuity wins approval for breast cancer drug Revtorpyk

With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma

Correction to Celcuity Gets FDA Approval Headline

Celcuity gains FDA approval for closely watched breast cancer drug

Kelun scores sac-TMT win in first-line NSCLC population missing from Merck’s massive phase 3 program

Celcuity's breast cancer drug approved, its first

Fierce Pharma Asia—GSK, Merck ADCs’ trial wins; AZ’s $1.5B EGFR buy; Biotechs’ new patent tricks

Celcuity got its cancer drug approved. Then its stock dipped